Business Centre - canada.com network

Neurochem stock falls despite plans to expand trials of Alzheimer's drug: "Shares of Neurochem Inc. fell 16 per cent Monday despite a relatively upbeat report by the Montreal biotechnology developer on clinical trials of its Alzheimer's disease drug."